Open Access

The cytotoxicity evaluation of magnetic iron oxide nanoparticles on human aortic endothelial cells

  • Gaoyuan Ge1, 2,
  • Hengfang Wu2,
  • Fei Xiong3,
  • Yu Zhang3,
  • Zhirui Guo4,
  • Zhiping Bian1,
  • Jindan Xu2,
  • Chunrong Gu1,
  • Ning Gu3,
  • Xiangjian Chen1Email author and
  • Di Yang2Email author
Contributed equally
Nanoscale Research Letters20138:215

DOI: 10.1186/1556-276X-8-215

Received: 14 March 2013

Accepted: 20 April 2013

Published: 7 May 2013


One major obstacle for successful application of nanoparticles in medicine is its potential nanotoxicity on the environment and human health. In this study, we evaluated the cytotoxicity effect of dimercaptosuccinic acid-coated iron oxide (DMSA-Fe2O3) using cultured human aortic endothelial cells (HAECs). Our results showed that DMSA-Fe2O3 in the culture medium could be absorbed into HAECs, and dispersed in the cytoplasm. The cytotoxicity effect of DMSA-Fe2O3 on HAECs was dose-dependent, and the concentrations no more than 0.02 mg/ml had little toxic effect which were revealed by tetrazolium dye assay. Meanwhile, the cell injury biomarker, lactate dehydrogenase, was not significantly higher than that from control cells (without DMSA-Fe2O3). However, the endocrine function for endothelin-1 and prostacyclin I-2, as well as the urea transporter function, was altered even without obvious evidence of cell injury in this context. We also showed by real-time PCR analysis that DMSA-Fe2O3 exposure resulted in differential effects on the expressions of pro- and anti-apoptosis genes of HAECs. Meanwhile, it was noted that DMSA-Fe2O3 exposure could activate the expression of genes related to oxidative stress and adhesion molecules, which suggested that inflammatory response might be evoked. Moreover, we demonstrated by in vitro endothelial tube formation that even a small amount of DMSA-Fe2O3 (0.01 and 0.02 mg/ml) could inhibit angiogenesis by the HAECs. Altogether, these results indicate that DMSA-Fe2O3 have some cytotoxicity that may cause side effects on normal endothelial cells.


Magnetic nanoparticles Iron oxide Endothelial cells Cell viability Angiogenesis


The application of magnetic nanoparticles (MNPs) in diagnosis and effective treatment of diseases has become an area of increasing interest in the biomedical sciences [14]. Drug delivery is used to carry drugs region-specifically by attaching them to MNPs and releasing the drug in vivo to the target locale [59]. Via AC magnetic fields, the MNPs can mediate hyperthermia for in situ cancer-targeted therapy and be used for in vitro cancer cell-targeted detecting systems [1014]. Similarly, cells of interest labeling with large amounts of MNPs can be located, tracked, and recovered by imaging techniques such as high-resolution magnetic resonance imaging [1518].

MNPs of iron oxide (Fe3O4, γ-Fe2O3) may develop to be the modest and biocompatible one with the rapid progress in biological applications research [19, 20]. Many investigations have studied the use of diverse organic coatings as a way of optimizing the delivery of MNPs to or into cell. Several studies have confirmed that a simple dimercaptosuccinic acid (DMSA) coating can enhance the rate of uptake by three orders of magnitude, presumptively by engendering the MNPs with an anionic charge, leading to nonspecific adsorption to the cell surface followed by endocytosis into the cell [2123]. These methods can deliver huge amounts of MNPs into the cells, but a proven concern arises over the impacts that great intracellular concentrations of MNPs might have on normal cell behavior. A quantitative model cell system indicates that intracellular delivery of even restrained levels of iron oxide (Fe2O3) nanoparticles may affect cell function. To be more specific, the cytotoxicity investigations show that exposure to mounting concentrations of anionic MNPs, from 0.15 to 15 mM of iron, results in a dose-dependent decreasing viability and capacity of PC12 cells to spread neurites in return for nerve growth factor [24].

In addition to drug delivery, many biomedical applications of MNPs such as magnetic tracking and hyperthermia need a very great deal of MNPs to be injected into blood vessels, which are lined by endothelial cells (ECs), a single squamous epithelial cell layer and an anticoagulant barrier between the vessel wall and blood. EC is involved in the immune and inflammatory response, coagulation, growth regulation, production of extracellular matrix components, and is a modulator of blood flow and blood vessel tone. EC injury, activation, or dysfunction is a hallmark of many pathologic states including atherosclerosis, loss of semi-permeable membrane function, and thrombosis [25]. A wide variety of stimuli can induce programmed cell death (apoptosis) of endothelial cells through extrinsic (death receptor) and/or intrinsic (mitochondria) apoptotic pathway, which is ultimately executed by the intracellular proteases called caspases. There also exist caspase-independent pathways of apoptosis and anti-apoptotic proteins, which can protect cells from apoptosis. These pathways and proteins compose the complicated network of the cell apoptosis [2629]. When injecting MNPs into blood vessels, ECs is the first tissue barrier encountered by the MNPs. The focus of this study is thus on the cytotoxicity evaluation of DMSA-coated Fe2O3 nanoparticles (DMSA-Fe2O3) on human aortic endothelial cell (HAEC), which is able to proliferate for many generations maintaining its endothelial characteristic and is widely used for in vitro study [30].



Dulbecco's modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were purchased from GIBCO Company (Grand Island, New York, USA). Endothelial cell growth supplement (ECGS) was supplied by M&C Gene Technology (Beijing, China). MEM non-essential amino acid solution (100×), l-glutamine, thiazolyl blue tetrazolium bromide, haematoxylin, penicillin, and streptomycin were obtained from Sigma-Aldrich (St Louis, MO, USA). Prostacyclin I-2 (PGI-2), endothelin-1 (ET-1), and nitric oxide (NO) assay kits were obtained from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). Primers were synthesized by Sangon Biotechnology Co., Ltd. (Shanghai, China), and RNAiso Plus reagent, PrimeScript™ RT reagent Kit, and SYBR Premix Ex Taq™ were from TaKaRa Biotechnology Co., Ltd. (Dalian, China). Matrigel basement membrane matrix was from Becton Dickinson (Bedford, MA, USA).

Preparation of DMSA-Fe2O3 nanoparticles

The DMSA-Fe2O3 was prepared by co-authors Dr. Fei Xiong, Dr. Yu Zhang, and Dr. Ning Gu. The characterization data, such as transmission electronic microscopy (TEM) images, crystal structure, surface charge, and magnetic measurements and Fourier transform infrared spectroscopy measurements were determined as the previous report in Dr. Gu's Lab [31]. In the present study, quasi-spherical DMSA-Fe2O3 with an average diameter of 10 nm, was diluted in deionized water to 1 mg/ml, and then further diluted in tested concentrations with cell culture medium before using.

Cell culture

HAECs were used for experiments at passages 2 to 5. HAECs were cultured in DMEM supplemented with 1% ECGS, 20% FBS, 1% heparin sodium, 1% non-essential amino acid solution (100×), 1% l-glutamine, 100 U/ml penicillin, and 100 U/ml streptomycin. Cells were maintained at 37°C in a humidified incubator with 5% CO2.

Location of DMSA-Fe2O3 in the HAEC

For TEM analysis, the HAECs incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h were washed with PBS and routinely fixed, dehydrated, and embedded [32]. Ultrathin sections (80 nm) were transferred to the 200 mesh copper grid, stained with 5% lead tetraacetate, air-dried, and then examined with a TEM (JEM-1010, JEOL, Akishima-shi, Japan) at 80 kV.

Cell viability/cytotoxicity assay

The cytotoxicity of DMSA-Fe2O3 against HAECs was investigated by the tetrazolium dye (MTT) assay [33]. For the dose-dependent effect, the DMSA-Fe2O3, diluted with culture medium at graded concentrations from 0.001 to 0.2 mg/ml, was applied to the HAECs for 24 h. For the time-dependent effect, 0.05 mg/ml of DMSA-Fe2O3 was applied to the cells for 4, 24, 48, and 72 h, respectively. After washing with PBS, the cells were incubated with MTT solution at 37°C for 2 h, and the dyes were dissolved by dimethyl sulfoxide (DMSO) for 15 min. Absorbance was examined at 595 nm with the Ultra Microplate Reader ELX808IU, and cell viability was calculated as a percentage of control cells treated without DMSA-Fe2O3. Each experiment was repeated at least three times independently.

Assessments of HAEC injury markers and endocrine factors

In this study, HAECs were co-cultured with 0.02 mg/ml of DMSA-Fe2O3 for 24 h. Then, the cell culture supernatant was centrifuged at 8000 × g, 4°C for 30 min to remove the rest of the nanoparticles and cell debris. ET-1, PGI-2, and NO concentrations in the supernatant were measured using ELISA kits according to the manufacturer's instructions, respectively. Lactate dehydrogenase (LDH) and urea were determined using an automatic biochemistry analyzer (Olympus AU5400, Olympus Corporation, Shinjuku-ku, Japan).

Real-time PCR analysis of HAEC gene expression

Thirty-eight genes related to apoptosis cascade, endoplasmic reticulum (ER) stress, oxidative stress, adhesion molecules, and calcium-handling proteins were detected by real-time PCR. In this study, HAECs were incubated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h. The total RNA (300 ng) extracted from HAECs was reverse-transcribed using the PrimeScript™ RT reagent Kit, and then the cDNA was amplified using the SYBR Premix Ex Taq™ according to the following cycle conditions: 30 s at 95°C for 1 cycle, 5 s at 95°C, and 30 s at 60°C for 40 cycles (AB 7900HT Fast Real-Time PCR system). All real-time PCR reactions were performed in triplicate. The housekeeping gene GAPDH was used as an internal control. The fold changes of target gene expression relative to those of the control group were analyzed by the 2-ΔΔCT method [34], divided into different ranges and depicted as different colors.

Effects of DMSA-Fe2O3 on HAEC tube formation

The tube formation assay is one of the most widely used assays to model the reorganization stage of angiogenesis in vitro. The assay measures the ability of endothelial cells, plated at subconfluent densities with the appropriate extracellular matrix support, to form capillary-like structures. In this study, the Matrigel basement membrane matrix was used as extracellular matrix support to observe whether angiogenesis of HAEC can be intervened by DMSA-Fe2O3 or not. For HAEC tube formation, 50 μl/well of the Matrigel basement membrane matrix was added to a 96-well plate and allowed to gel for 60 min at 37°C. Then, HAECs were seeded at a density of 1.5 × 104 cells/well on the surface of the gel in the presence or absence of conditioned DMSA-Fe2O3 and incubated for 14 h at 37°C in a CO2 incubator. Meanwhile, the high urea solution (6M urea) was used as a positive control for inhibition of tube formation. The cultures on the gel were fixed for 10 min in 25% glutaraldehyde, washed, and stained with Mayer’s hematoxylin. Each well was inspected under a light microscope at ×100 magnification and captured more than three pictures from different fields. Image-Pro plus (IPP) 6.0 for Windows software (Media Cybernetics, Inc., Rockville, MD, USA) was used to measure the length of tube formation on each picture. The average data from the same well was calculated as its quantitative value.

Statistical analysis

The data were represented as mean ± SD of no less than three independent experiments. Statistical analysis was performed using a student's t test. A value of p < 0.05 was considered statistically significant.

Results and discussion

Endocytosis of DMSA-Fe2O3 by HAECs

We were able to recognize the DMSA-Fe2O3 inside the HAECs and distinguish them from the cellular structures by their high electron density on TEM. Figure 1 represents TEM micrographic images between HAECs incubation with 0.02 mg/ml of DMSA-Fe2O3 (Figure 1c,d) and HAECs without DMSA-Fe2O3 incubation (Figure 1a,b). The results indicate that the DMSA-Fe2O3 aggregates are readily absorbed by the cells without disrupting the integrity of the cellular membrane and dispersed in the cytoplasm.
Figure 1

The TEM images of HAECs incubated with 0.02 mg/ml of DMSA-Fe 2 O 3 for 24 h. (a) HAEC without DMSA-Fe2O3 (×8,000). (b) HAEC without DMSA-Fe2O3 (×30,000). (c) HAEC incubated with DMSA-Fe2O3 (×5,000). (d) HAEC incubated with DMSA-Fe2O3 (×30,000). Abbreviations: n, nucleus; v, vesicle; Arrows denote the DMSA-Fe2O3 or particulate matter.

HAECs viability studies

The tetrazolium dye (MTT) assay has been used for detecting the number of viable cells (proliferation) and loss of viable cells (cytotoxicity) resulting from toxic materials since only living cells can reduce the MTT to its insoluble form, formazan, which can be quantitatively measured after dissolved in DMSO by a spectrophotometer, and the resultant value is linked to the number of living cells [35].

In the present study, the viability of HAECs was apparently decreased with increased DMSA-Fe2O3 concentrations compared with that of control cells (Figure 2a). HAECs treated with the concentrations under 0.05 mg/ml of DMSA-Fe2O3 for 24 h did not induce any cell losses. In contrast, DMSA-Fe2O3 at the high doses (greater than 0.05 mg/ml) resulted in significant cell loss thereby cytotoxic. The cell viability of HAECs incubated with DMSA-Fe2O3 at the concentration of 0.2 mg/ml was approximately decreased to 56.7% of the control cells.
Figure 2

The viability of HAECs incubated with DMSA-Fe 2 O 3 . Data are expressed as mean ± SD from independent experiments. Control values from HAECs incubated without DMSA-Fe2O3 were defined as 1. (a) HAECs were incubated with DMEM containing the gradient concentrations of DMSA-Fe2O3 for 24 h (0.001, 0.01, 0.02, 0.05, 0.1, 0.2 mg/ml), n = 7. (b) HAECs were incubated with DMEM containing 0.05 mg/ml DMSA-Fe2O3 for the indicated time (4, 24, 48, 72 h). n = 5. *p < 0.05 vs. control; **p < 0.01 vs. control.

To study the time-dependent effect of DMSA-Fe2O3 on HAECs viability, cells were incubated with 0.05 mg/ml of DMSA-Fe2O3 for 4, 24, 48, and 72 h, respectively (Figure 2b). Decreased cell viability occurred as early as 4 h and varied in a range from 75.8% to 93.1% to the control group at tested time points. The results suggest that the cytotoxic effect of DMSA-Fe2O3 on HAECs is dose-dependent, and the concentrations no more than 0.02 mg/ml are relatively harmless in the present study.

Effects of DMSA-Fe2O3 on HAEC injury markers and endocrine factors

LDH is a cytoplasmic enzyme which can be released to the extracellular space because of the disturbances of the cellular integrity induced by pathological conditions. Therefore, supernatant LDH of cultured HAECs is detected as a marker for cell injury [36]. We found that there was no difference in LDH released from the HAECs incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h and the control cells (Figure 3). This finding was consistent with the results of little cytotoxicity effect in MTT assay (Figure 2a) and cell membrane integrity changes shown by TEM (Figure 1c,d).
Figure 3

Levels of injury marker, LDH, and endocrine factors in supernatant of HAECs. Incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h. Ratios relative to the control cells (without DMSA-Fe2O3) are shown. *p < 0.05 vs. control; **p < 0.01 vs. control.

We then examined whether the endocrine function of HAECs was changed when exposed to this low dose of DMSA-Fe2O3 that did not cause measurable cell injury. ECs can regulate blood pressure and blood flow by releasing vasodilators such as NO and PGI-2, as well as vasoconstrictors, including ET-1. So, the endocrine function of cultured HAECs can be assessed by detecting the above-mentioned factors in the supernatant. We found that the release of NO was not changed in the HAECs treated with 0.02 mg/ml DMSA-Fe2O3 for 24 h (Figure 3). NO released toward the vascular lumen is the most important stimulator for vascular dilator and a potent inhibitor of platelet aggregation and adhesion. NO protects against the onset and later steps in atherogenesis, and thus is one of the most important protective molecules in the vasculature. Endothelial NO synthase (eNOS) is the predominant NOS isoform in the vasculature responsible for most of the vascular NO production. A functional eNOS oxidizes its substrate l-arginine to l-citrulline and NO. Our results indicate that the eNOS function in the HAECs is not affected by treatment with 0.02 mg/ml DMSA-Fe2O3 for 24 h.

In contrast to the release of NO, the release of another vasodilator PGI-2 and the vasoconstrictor ET-1 was significantly decreased in the HAECs treated with 0.02 mg/ml DMSA-Fe2O3 for 24 h (Figure 3, p < 0.01 vs. control group). Besides its function as an effective vasodilator, PGI-2 can prevent platelet plug formation by inhibiting platelet activation. PGI-2 is produced in endothelial cells from prostaglandin H2 by the action of the enzyme PGI-2 synthase. ET-1 is secreted constitutively by endothelial cells from its inactive intermediate, big ET-1, through the action of endothelin-converting enzyme, which is present at the EC surface and on intracellular vesicles. Expression and release of PGI-2 and ET-1 in the ECs are regulated by complex signals; we did not study the mechanism for their reducing expressions and/or release in this study. However, our results demonstrate that the endocrine functions of HAECs are sensitive to DMSA-Fe2O3 treatment, and these functions may be interfered before severe cell injuries occur.

In addition to the cellular-releasing function of these vessel tone regulators, we also studied the cellular uptake function by examining the urea transporter function. The transporter for urea is expressed in the vascular endothelium that transports urea into the cell. Urea plays a significant role in the endothelial cell, and previous studies have revealed that uremic levels of urea (25 mM) inhibit l-arginine transport in cultured endothelial cells [37]. In this study, we found that the urea concentration in the HAECs treated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h was significantly higher than that in control cells (Figure 3, p < 0.05). This observation suggests that the function of urea transporter in the HAECs is also inhibited by the DMSA-Fe2O3 exposure.

Gene expression on HAECs

Endothelial cell death, which can be caused by environmental stresses such as oxidative stress, endoplasmic reticulum stress, and adhesion molecules, is mostly apoptotic [26]. We thereby examined gene expression related to the apoptosis cascade, endoplasmic reticulum stress, oxidative stress, adhesion molecules, and calcium-handling proteins (Figure 4). After the HAECs were incubated with 0.02 mg/ml of DMSA-Fe2O3 for 24 h, the expressions of most of genes involved in the apoptosis cascade and calcium-handling proteins were changed from 0.5- to 1.5-fold compared to those of HAECs without DMSA-Fe2O3 treatment, except MAPK14 (mitogen-activated protein kinase 14, MAPK14, also called p38-α), CASP3 (caspase 3), and BCL2 (Bcl-2). Caspase 3 [38] and Bcl-2 [27], which promote cell death and inhibit cell death, respectively, were increased by over 1.5-fold in mRNA expression in the experiment group. In contrast, the expression of proapoptotic MAPK14[39] in DMSA-Fe2O3-treated HAECs was decreased to less than 0.5-fold to that of the control cells. Therefore, the DMSA-Fe2O3 caused differential effects on the expression of pro- and anti-apoptosis genes of HAECs; this may explain why the viability of HAECs was not changed at this low concentration of DMSA-Fe2O3, which might not be sufficient to activate the cell apoptosis pathway.
Figure 4

Fold changes in gene expression: apoptosis, adhesion molecules, ER stress, oxidative stress, and calcium-handling proteins. The changes of HAECs incubated with 0.02 mg/ml DMSA-Fe2O3 for 24 h to control the cells (HAECs without DMSA-Fe2O3) were analyzed by the 2-ΔΔCT method. Gene symbols and corresponding encoded proteins: MAP3K5, apoptosis signal-regulating kinase 1 (ASK1); TRAF2, tumor necrosis factor receptor-associated factor 2 (TRAF2); DAB2IP, ASK1-interacting protein (AIP1); MAPK8, mitogen-activated protein kinase 8 (JNK1); MAPK9, mitogen-activated protein kinase 9 (JNK2); MAPK14, mitogen-activated protein kinase 14 (p38 MAPK α); ERN1, endoplasmic reticulum to nucleus signaling 1 (IRE1); BCL2, B-cell lymphoma 2 (Bcl-2); BAX, Bcl-2-associated X protein (Bax); NKRF, nuclear factor-κB repressing factor; TXN, thioredoxin; CTSB, cathespin B; CYCS, cytochrome C; CASP9, caspase-9; CASP3, caspase-3; EIF2AK3, eukaryotic translation initiation factor 2α kinase 3 (PERK); ATF4, activating transcription factor 4; DDIT3, DNA-damage-inducible transcript 3 (CHOP); EIF2A, eukaryotic translation initiation factor 2α; NOS3, nitric oxide synthase 3 (eNOS); SOD1, super oxide dismutase 1 (SOD-1); SOD2, super oxide dismutase 2 (SOD-2); ROMO1, reactive oxygen species modulator 1; PTGS1, cyclooxygenase 1 (COX-1); PTGS2, cyclooxygenase 2 (COX-2); VCAM1, vascular cell adhesion molecule 1 (VCAM-1); ICAM1, intercellular adhesion molecule 1(ICAM-1); ICAM2, intercellular adhesion molecule 2 (ICAM-2); SELE, endothelial-leukocyte adhesion molecule 1 (E-selectin); PLCG1, phospholipase C γ1; PLCG2, phospholipase C γ2; ITPR1, inositol 1,4,5-trisphosphate receptor type 1; ITPR2, inositol 1,4,5-trisphosphate receptor type 2; ITPR3, inositol 1,4,5-trisphosphate receptor type 3; CALM1, calmodulin 1.

In this study, the expressions of all four tested genes involved in ER stress, were down-regulated in DMSA-Fe2O3-treated HAECs (Figure 4), especially the AFT4 gene (activating transcription factor 4), whose expression was decreased by over 50%. In contrast, most of the examined genes related to oxidative stress showed an increased change in DMSA-Fe2O3-treated HAECs with the expression of SOD2 (superoxide dismutase 2) and PTGS2 (cyclooxygenase-2, COX-2) elevated to 1.96- and 2.44-fold, respectively. COX-2 is unexpressed under the normal conditions but elevated during an inflammation. The data suggest that oxidative stress, not ER stress, is sensitive to DMSA-Fe2O3. In addition, the expression of NOS3 (eNOS) was mildly decreased in DMSA-Fe2O3-treated HAECs, which was consistent to the result of NO concentration (Figure 3).

We found up-regulation of gene expression for cell-cell contact and adhesion including ICAM1 (intercellular adhesion molecule 1, ICAM-1), VCAM1 (vascular cell adhesion protein 1, VCAM-1), and SELE (endothelial-leukocyte adhesion molecule 1, E-selectin) (3.3-, 4.9-, and 8.1-fold, respectively, Figure 4). ICAM-1 is a type of intercellular adhesion molecule which continuously presents in low concentrations in the membranes of leukocytes and endothelial cells, and greatly increases upon cytokine stimulation. VCAM-1 and E-selectin are cell adhesion molecules expressed only after the endothelial cells being stimulated by cytokines and thus play an important role in inflammation. Thus, together with the data from genes associated with oxidative stress, the results of adhesion molecular genes indicate that inflammation response is likely evoked in HAECs following 0.02 mg/ml DMSA-Fe2O3 treatment before the onset of cell death.

Effects of DMSA-Fe2O3 on HAECs tube formation

Angiogenesis, the formation of new capillaries from preexisting blood vessels, is a motile process involving ECs activation. The migration of ECs is essential to angiogenesis and this complex process may be induced by kinds of mediators including cytokines, growth factors, and cell adhesion molecules. In physiological conditions, angiogenesis occurs in development and wound healing. However, pathological angiogenesis plays an essential role in cancer cell growth. The inhibition or antagonism of angiogenesis has been the focus of extensive basic and clinical research [40, 41]. To further determine the effect of DMSA-Fe2O3 on angiogenesis by the HAECs, we performed endothelial tube formation assay using the Matrigel basement membrane matrix. We found that while HAECs without DMSA-Fe2O3 treatment formed a capillary-like network on Matrigel-coated wells within 14 h (Figure 5a), on the opposite, HAECs treated with 6M urea failed to form tubes due to its high osmolality (Figure 5d). Importantly, an obvious failure to form networks by the HAECs in the presence of DMSA-Fe2O3 with 0.01 (Figure 5b) and 0.02 mg/ml (Figure 5c) concentrations was observed. The length of the formed tube was decreased to 42.5% and 19.1% of the normal control at 0.01 and 0.02 mg/ml DMSA-Fe2O3, respectively (Figure 6). The elevated expressions of cell adhesion molecules might be responsible for the failed tube formation. The angiogenesis assay suggests that even a small amount of DMSA-Fe2O3 is also harmful to the angiogenesis of normal endothelial cells, which is an essential process in embryo development and wound healing.
Figure 5

Effect of DMSA-Fe 2 O 3 on tube network formed by HAECs cultured on Matrigel within 14 h. (a) HAECs can form a capillary-like network on Matrigel-coated wells within 14 h. (b) An obvious failure to form networks by HAECs in the presence of 0.01 mg/ml DMSA-Fe2O3. (c) Few tube networks by HAECs in the presence of 0.02 mg/ml DMSA-Fe2O3. (d) The high urea solution (6M urea) was used as a positive control for the inhibition of tube formation.
Figure 6

Length of tube networks formed by HAEC cultured on Matrigel. Image-Pro plus 6.0 for Windows software was used to measure the length of tube networks (pixels). The stained cells were inspected under a light microscope at ×100 magnification and captured more than three pictures from different fields. The average data from the same well was calculated as its quantitative value. Data are expressed as mean ± SD. **p < 0.01 vs. control.


In summary, the present study shows that DMSA-Fe2O3 nanoparticles absorbed by the HAECs can cause a dose-dependent cytotoxic event. HAECs exposed to even a small amount of DMSA-Fe2O3 may have impaired endocrine function and angiogenic functions without obvious cell toxicity. Furthermore, the genes related to oxidative stress and inflammation response were activated. Therefore, cautious evaluation of DMSA-Fe2O3 nanoparticles in vivo is needed before applying them in medicine.




This work was supported by the National Natural Science Foundation of China (nos. 81170220 and 81100156), Jiangsu Province Health Foundation (RC2011075), and the Open Project by Jiangsu Key Laboratory for Biomaterials and Devices. We would like to thank Dr. Bin Zhou (Department of Genetics, Albert Einstein College of Medicine of Yeshiva University, New York, USA) for the critical reading, advice, and comments of the manuscript.

Authors’ Affiliations

Research Institute of Cardiovascular Disease, First Affiliated Hospital of Nanjing Medical University
Department of Cardiology, First Affiliated Hospital of Nanjing Medical University
State Key Laboratory of Molecule and Biomolecule Electronics, Jiangsu Provincial Laboratory for Biomaterials and Devices, Southeast University
Second Affiliated Hospital of Nanjing Medical University, Nanjing


  1. Sjogren CE, Johansson C, Naevestad A, Sontum PC, Briley-Saebo K, Fahlvik AK: Crystal size and properties of superparamagnetic iron oxide (SPIO) particles. Magn Reson Imaging 1997, 15: 55–67. 10.1016/S0730-725X(96)00335-9View ArticleGoogle Scholar
  2. Halbreich A, Roger J, Pons JN, Geldwerth D, Da Silva MF, Roudier M, Bacri JC: Biomedical applications of maghemite ferrofluid. Biochimie 1998, 80: 379–390. 10.1016/S0300-9084(00)80006-1View ArticleGoogle Scholar
  3. Perez JM, O'Loughin T, Simeone FJ, Weissleder R, Josephson L: DNA-based magnetic nanoparticle assembly acts as a magnetic relaxation nanoswitch allowing screening of DNA-cleaving agents. J Am Chem Soc 2002, 124: 2856–2857. 10.1021/ja017773nView ArticleGoogle Scholar
  4. Dyal A, Loos K, Noto M, Chang SW, Spagnoli C, Shafi KV, Ulman A, Cowman M, Gross RA: Activity of Candida rugosa lipase immobilized on gamma-Fe2O3 magnetic nanoparticles. J Am Chem Soc 2003, 125: 1684–1685. 10.1021/ja021223nView ArticleGoogle Scholar
  5. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lubbe AS: Locoregional cancer treatment with magnetic drug targeting. Cancer Res 2000, 60: 6641–6648.Google Scholar
  6. Vasir JK, Labhasetwar V: Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005, 4: 363–374.View ArticleGoogle Scholar
  7. Zhang R, Wang X, Wu C, Song M, Li J, Lv G, Zhou J, Chen C, Dai Y, Gao F, Fu D, Li X, Guan Z, Chen B: Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology 2006, 17: 3622–3626. 10.1088/0957-4484/17/14/043View ArticleGoogle Scholar
  8. Arruebo M, Fernández-Pacheco R, Ibarra MR, Santamaría J: Magnetic nanoparticles for drug delivery. Nano Today 2007, 2: 22–32.View ArticleGoogle Scholar
  9. Dandamudi S, Campbell RB: The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. Biomaterials 2007, 28: 4673–4683. 10.1016/j.biomaterials.2007.07.024View ArticleGoogle Scholar
  10. Jordan A, Scholz R, Maier-Hauff K, van Landeghem FK, Waldoefner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling A, Felix R: The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2006, 78: 7–14. 10.1007/s11060-005-9059-zView ArticleGoogle Scholar
  11. Ito A, Shinkai M, Honda H, Kobayashi T: Heat-inducible TNF-alpha gene therapy combined with hyperthermia using magnetic nanoparticles as a novel tumor-targeted therapy. Cancer Gene Ther 2001, 8: 649–654. 10.1038/sj.cgt.7700357View ArticleGoogle Scholar
  12. Moroz P, Jones SK, Gray BN: Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 2002, 18: 267–284. 10.1080/02656730110108785View ArticleGoogle Scholar
  13. Kawashita M, Tanaka M, Kokubo T, Inoue Y, Yao T, Hamada S, Shinjo T: Preparation of ferrimagnetic magnetite microspheres for in situ hyperthermic treatment of cancer. Biomaterials 2005, 26: 2231–2238. 10.1016/j.biomaterials.2004.07.014View ArticleGoogle Scholar
  14. Chen L, Bao CC, Yang H, Li D, Lei C, Wang T, Hu HY, He M, Zhou Y, Cui DX: A prototype of giant magnetoimpedance-based biosensing system for targeted detection of gastric cancer cells. Biosens Bioelectron 2011, 26: 3246–3253. 10.1016/j.bios.2010.12.034View ArticleGoogle Scholar
  15. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R: Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000, 18: 410–414. 10.1038/74464View ArticleGoogle Scholar
  16. Kircher MF, Rhea JT, Kihiczak D, Novelline RA: Frequency, sensitivity, and specificity of individual signs of diverticulitis on thin-section helical CT with colonic contrast material: experience with 312 cases. AJR Am J Roentgenol 2002, 178: 1313–1318. 10.2214/ajr.178.6.1781313View ArticleGoogle Scholar
  17. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, Bhattarai N, Ellenbogen R, Sze R, Hallahan A, Olson J, Zhang M: Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005, 5: 1003–1008. 10.1021/nl0502569View ArticleGoogle Scholar
  18. Jun YW, Huh YM, Choi JS, Lee JH, Song HT, Kim S, Yoon S, Kim KS, Shin JS, Suh JS, Cheon J: Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc 2005, 127: 5732–5733. 10.1021/ja0422155View ArticleGoogle Scholar
  19. Gojova A, Guo B, Kota RS, Rutledge JC, Kennedy IM, Barakat AI: Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ Health Perspect 2007, 115: 403–409. 10.1289/ehp.115-a403View ArticleGoogle Scholar
  20. Muller K, Skepper JN, Posfai M, Trivedi R, Howarth S, Corot C, Lancelot E, Thompson PW, Brown AP, Gillard JH: Effect of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) on human monocyte-macrophages in vitro. Biomaterials 2007, 28: 1629–1642. 10.1016/j.biomaterials.2006.12.003View ArticleGoogle Scholar
  21. Wilhelm C, Gazeau F, Bacri JC: Magnetophoresis and ferromagnetic resonance of magnetically labeled cells. Eur Biophys J 2002, 31: 118–125. 10.1007/s00249-001-0200-4View ArticleGoogle Scholar
  22. Billotey C, Wilhelm C, Devaud M, Bacri JC, Bittoun J, Gazeau F: Cell internalization of anionic maghemite nanoparticles: quantitative effect on magnetic resonance imaging. Magn Reson Med 2003, 49: 646–654. 10.1002/mrm.10418View ArticleGoogle Scholar
  23. Wilhelm C, Billotey C, Roger J, Pons JN, Bacri JC, Gazeau F: Intracellular uptake of anionic superparamagnetic nanoparticles as a function of their surface coating. Biomaterials 2003, 24: 1001–1011. 10.1016/S0142-9612(02)00440-4View ArticleGoogle Scholar
  24. Pisanic TR 2nd, Blackwell JD, Shubayev VI, Finones RR, Jin S: Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28: 2572–2581. 10.1016/j.biomaterials.2007.01.043View ArticleGoogle Scholar
  25. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Schmidt AM, Stern DM: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91: 3527–3561.Google Scholar
  26. Pober JS, Min W, Bradley JR: Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol 2009, 4: 71–95. 10.1146/annurev.pathol.4.110807.092155View ArticleGoogle Scholar
  27. Chen J, Mehta JL, Haider N, Zhang X, Narula J, Li D: Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004, 94: 370–376. 10.1161/01.RES.0000113782.07824.BEView ArticleGoogle Scholar
  28. Winn RK, Harlan JM: The role of endothelial cell apoptosis in inflammatory and immune diseases. J Thromb Haemost 2005, 3: 1815–1824. 10.1111/j.1538-7836.2005.01378.xView ArticleGoogle Scholar
  29. Gu X, Yao Y, Cheng R, Zhang Y, Dai Z, Wan G, Yang Z, Cai W, Gao G, Yang X: Plasminogen K5 activates mitochondrial apoptosis pathway in endothelial cells by regulating Bak and Bcl-x(L) subcellular distribution. Apoptosis 2011, 16: 846–855. 10.1007/s10495-011-0618-9View ArticleGoogle Scholar
  30. Donnini D, Perrella G, Stel G, Ambesi-Impiombato FS, Curcio F: A new model of human aortic endothelial cells in vitro. Biochimie 2000, 82: 1107–1114. 10.1016/S0300-9084(00)01195-0View ArticleGoogle Scholar
  31. Zhang S, Chen X, Gu C, Zhang Y, Xu J, Bian Z, Yang D, Gu N: The effect of iron oxide magnetic nanoparticles on smooth muscle cells. Nanoscale Res Lett 2008, 4: 70–77.View ArticleGoogle Scholar
  32. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P: Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem 2005, 16: 1181–1188. 10.1021/bc050050zView ArticleGoogle Scholar
  33. Gupta AK, Berry C, Gupta M, Curtis A: Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans Nanobioscience 2003, 2: 255–261. 10.1109/TNB.2003.820279View ArticleGoogle Scholar
  34. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25: 402–408. 10.1006/meth.2001.1262View ArticleGoogle Scholar
  35. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65: 55–63. 10.1016/0022-1759(83)90303-4View ArticleGoogle Scholar
  36. Chopra J, Joist JH, Webster RO: Loss of 51chromium, lactate dehydrogenase, and 111indium as indicators of endothelial cell injury. Lab Invest 1987, 57: 578–584.Google Scholar
  37. Xiao S, Wagner L, Mahaney J, Baylis C: Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 2001, 280: F989-F995.Google Scholar
  38. Lee YW, Kuhn H, Hennig B, Toborek M: IL-4 induces apoptosis of endothelial cells through the caspase-3-dependent pathway. FEBS Lett 2000, 485: 122–126. 10.1016/S0014-5793(00)02208-0View ArticleGoogle Scholar
  39. Ferrari G, Terushkin V, Wolff MJ, Zhang X, Valacca C, Poggio P, Pintucci G, Mignatti P: TGF-beta1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38beta to proapoptotic p38alpha. Mol Cancer Res 2012, 10: 605–614. 10.1158/1541-7786.MCR-11-0507View ArticleGoogle Scholar
  40. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, Reinmuth N: Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 2001, 28: 94–104.View ArticleGoogle Scholar
  41. Kerbel RS: Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21: 505–515. 10.1093/carcin/21.3.505View ArticleGoogle Scholar


© Ge et al.; licensee Springer. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.